drugset / Trial / NCT01161472

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

NCT01161472

Phase 1 Completed 20 enrolled Pfizer
RandomizedCrossoverQuadruple-blind

Summary

The study is designed to evaluate elements of cognitive function in subjects receiving either fesoterodine or alprazolam.

Timeline

Start
2010-07
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alprazolam Small molecule 1 mg
Subject Fesoterodine Other / unclassified 4 mg
Subject Fesoterodine Other / unclassified 8 mg

Indications

No indication recorded.